Eikon steps down into Nasdaq
With a slashed valuation the newly listed biotech heads for phase 3.
Novartis prunes its pipeline
An actinium-based backup and Werner helicase inhibitor are notable absences.
Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Like MacroGenics, Sanofi tries to square an uneasy circle
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
